The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: past activities, current status and future direction
The Lung Cancer Surgical Study Group was established in 1986. In this review, we outline the Lung Cancer Surgical Study Group activities of the past 30 years and future prospects.
Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer
Matched-pair analysis including disease-free interval, pattern of recurrence and number of recurrent regions revealed that elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer
Hepato-biliary and pancreatic Surgery
Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature
Analysis of clinical data showed that surgery for recurrent biliary tract cancer prolongs survival in select patients.
Palliative and supportive care
Collaborative care intervention for the perceived care needs of women with breast cancer undergoing adjuvant therapy after surgery: a feasibility study
Our collaborative care intervention for the perceived unmet care needs of women with breast cancer undergoing adjuvant therapy after surgery was feasible. The preliminary results suggest the program was effective.
Utility of rapid on-site cytologic evaluation during endobronchial ultrasound with a guide sheath for peripheral pulmonary lesions
Rapid on-site evaluation may be valuable during endobronchial ultrasound with a guide sheath for the diagnosis of peripheral pulmonary lesions, but careful interpretation of results and correlation with the clinical presentation are necessary.
Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma
Second-line tumor burden was an independent predictor of overall survival among patients with metastatic renal cell carcinoma after second-line molecular-targeted therapy.
A positive surgical margin predicted biochemical recurrence in both the early and late periods after radical prostatectomy for clinically localized prostate cancer.
Systematic regional lymph node dissection for upper tract urothelial carcinoma improves patient survival
Systematic regional lymph node dissection during radical nephroureterectomy for cTanyN0M0 upper tract urothelial carcinoma patients has a significantly beneficial impact on survival, especially in the cases involving muscle invasion.
The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial
A single-arm multi-institutional phase II trial (JMTO Pca 10-01) of docetaxel-based chemotherapy combined with dexamethasone showed a significant high PSA response rate (76.8%) compared with previous Japanese phase II trial.
The feasibility and effectiveness of robot-assisted radical cystectomy after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
Neoadjuvant chemotherapy followed by robot-assisted radical cystectomy may have acceptable operative and perioperative clinical outcomes for muscle-invasive bladder cancer patients.
For locally advanced prostate cancer, aggressive treatment with short-term androgen deprivation could be beneficial without serious adverse effect.
Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results
Longer term efficacy results in Japanese patients enrolled in PREVAIL demonstrate continued treatment benefit of enzalutamide compared with placebo in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
Public Health Report
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis
A meta-analysis evaluating the immunogenicity and safety of HPV vaccines in Asian population, particularly on both infected and uninfected individuals.
Clinical Trial Note
A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial)
A randomized Phase III trial comparing two dose fractionations (42 vs 55 Gy) of stereotactic body radiotherapy for medically inoperable Stage IA non-small cell lung cancer commenced in Japan in February 2016.